These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38536824)

  • 1. Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets.
    Ocan M; Nambatya W; Otike C; Nakalembe L; Nsobya S
    PLoS One; 2024; 19(3):e0295198. PubMed ID: 38536824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to quality-assured artemisinin-based combination therapy and associated factors among clients of selected private drug outlets in Uganda.
    Ocan M; Nakalembe L; Otike C; Mordecai T; Birungi J; Nsobya S
    Malar J; 2024 Apr; 23(1):128. PubMed ID: 38689257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience of healthcare personnel on Co-payment mechanism and the implications on its use in private drug outlets in Uganda.
    Ocan M; Bakubi R; Nakalembe L; Ekusai-Sebatta D; Sam N
    PLoS One; 2024; 19(5):e0297416. PubMed ID: 38758832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data.
    Tougher S; ; Ye Y; Amuasi JH; Kourgueni IA; Thomson R; Goodman C; Mann AG; Ren R; Willey BA; Adegoke CA; Amin A; Ansong D; Bruxvoort K; Diallo DA; Diap G; Festo C; Johanes B; Juma E; Kalolella A; Malam O; Mberu B; Ndiaye S; Nguah SB; Seydou M; Taylor M; Rueda ST; Wamukoya M; Arnold F; Hanson K
    Lancet; 2012 Dec; 380(9857):1916-26. PubMed ID: 23122217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries.
    O'Connell KA; Gatakaa H; Poyer S; Njogu J; Evance I; Munroe E; Solomon T; Goodman C; Hanson K; Zinsou C; Akulayi L; Raharinjatovo J; Arogundade E; Buyungo P; Mpasela F; Adjibabi CB; Agbango JA; Ramarosandratana BF; Coker B; Rubahika D; Hamainza B; Chapman S; Shewchuk T; Chavasse D
    Malar J; 2011 Oct; 10():326. PubMed ID: 22039838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-sectional study of the availability and price of anti-malarial medicines and malaria rapid diagnostic tests in private sector retail drug outlets in rural Western Kenya, 2013.
    Kioko U; Riley C; Dellicour S; Were V; Ouma P; Gutman J; Kariuki S; Omar A; Desai M; Buff AM
    Malar J; 2016 Jul; 15(1):359. PubMed ID: 27406179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two years post affordable medicines facility for malaria program: availability and prices of anti-malarial drugs in central Ghana.
    Freeman A; Kwarteng A; Febir LG; Amenga-Etego S; Owusu-Agyei S; Asante KP
    J Pharm Policy Pract; 2017; 10():15. PubMed ID: 28465829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism.
    ; Tougher S; Hanson K; Goodman C
    Malar J; 2017 Apr; 16(1):173. PubMed ID: 28441956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.
    van der Pluijm RW; Tripura R; Hoglund RM; Pyae Phyo A; Lek D; Ul Islam A; Anvikar AR; Satpathi P; Satpathi S; Behera PK; Tripura A; Baidya S; Onyamboko M; Chau NH; Sovann Y; Suon S; Sreng S; Mao S; Oun S; Yen S; Amaratunga C; Chutasmit K; Saelow C; Runcharern R; Kaewmok W; Hoa NT; Thanh NV; Hanboonkunupakarn B; Callery JJ; Mohanty AK; Heaton J; Thant M; Gantait K; Ghosh T; Amato R; Pearson RD; Jacob CG; Gonçalves S; Mukaka M; Waithira N; Woodrow CJ; Grobusch MP; van Vugt M; Fairhurst RM; Cheah PY; Peto TJ; von Seidlein L; Dhorda M; Maude RJ; Winterberg M; Thuy-Nhien NT; Kwiatkowski DP; Imwong M; Jittamala P; Lin K; Hlaing TM; Chotivanich K; Huy R; Fanello C; Ashley E; Mayxay M; Newton PN; Hien TT; Valecha N; Smithuis F; Pukrittayakamee S; Faiz A; Miotto O; Tarning J; Day NPJ; White NJ; Dondorp AM;
    Lancet; 2020 Apr; 395(10233):1345-1360. PubMed ID: 32171078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to artemisinin-based combination therapy (ACT) and quinine in malaria holoendemic regions of western Kenya.
    Watsierah CA; Ouma C
    Malar J; 2014 Jul; 13():290. PubMed ID: 25066600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Private sector role, readiness and performance for malaria case management in Uganda, 2015.
    ; Kaula H; Buyungo P; Opigo J
    Malar J; 2017 May; 16(1):219. PubMed ID: 28545583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The malaria testing and treatment landscape in mainland Tanzania, 2016.
    ; Michael D; Mkunde SP
    Malar J; 2017 Apr; 16(1):202. PubMed ID: 28521811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing availability, prices, and market share of quality-assured malaria ACT and RDT in the private retail sector in Nigeria and Uganda.
    Woldeghebriel M; Aso E; Berlin E; Fashanu C; Kirumira SN; Lam F; Mugerwa R; Nakiganda J; Olaleye T; Opigo J; Osinupebi F; Priestley N; Stringham R; Uhomoibhi P; Visser T; Ward A; Wiwa O; Woolsey A
    Malar J; 2024 Feb; 23(1):41. PubMed ID: 38321459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in access to anti-malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first-line anti-malarials and diagnostics between 2007 and 2018.
    Kibira D; Ssebagereka A; van den Ham HA; Opigo J; Katamba H; Seru M; Reed T; Leufkens HG; Mantel-Teeuwisse AK
    Malar J; 2021 Mar; 20(1):142. PubMed ID: 33691704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The malaria testing and treatment landscape in Benin.
    ; Zinsou C; Cherifath AB
    Malar J; 2017 Apr; 16(1):174. PubMed ID: 28446236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries.
    Davis B; Ladner J; Sams K; Tekinturhan E; de Korte D; Saba J
    Malar J; 2013 Apr; 12():135. PubMed ID: 23607504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsidising artemisinin-based combination therapy in the private retail sector.
    Opiyo N; Yamey G; Garner P
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009926. PubMed ID: 26954551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing times: trends in availability, price, and market share of malaria diagnostics in the public and private healthcare sector across eight sub-Saharan African countries from 2009 to 2015.
    ; Hanson K; Goodman C
    Malar J; 2017 May; 16(1):205. PubMed ID: 28526075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has Tanzania embraced the green leaf? Results from outlet and household surveys before and after implementation of the Affordable Medicines Facility-malaria.
    Thomson R; Festo C; Johanes B; Kalolella A; Bruxvoort K; Nchimbi H; Tougher S; Cairns M; Taylor M; Kleinschmidt I; Ye Y; Mann A; Ren R; Willey B; Arnold F; Hanson K; Kachur SP; Goodman C
    PLoS One; 2014; 9(5):e95607. PubMed ID: 24816649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do anti-malarials in Africa meet quality standards? The market penetration of non quality-assured artemisinin combination therapy in eight African countries.
    ; Newton PN; Hanson K; Goodman C
    Malar J; 2017 May; 16(1):204. PubMed ID: 28539125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.